Neoplastic Syndrome Completed Phase 2 Trials for Motesanib (DB05575)

Also known as: Neoplastic disease (disorder)

IndicationStatusPhase
DBCOND0028594 (Neoplastic Syndrome)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00427349AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsTreatment